« Back
Home /
Sitagliptin

Sitagliptin

Item no.	HY-13749-100mg
Manufacturer	MedChem Express
CASRN	486460-32-6
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 200 mg 500 mg
Category	Neuroscience Aging & Neurological Disorders Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.75
Citations	[1]Thomas, L., et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325(1):175-82.\|[2]Kim, S.J., et al., Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes, 2009. 58(3): p. 641-51.\|[3]Sangle, G.V., et al., Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a GLP-1 secretagogue. Endocrinology, 2012. 153(2): p. 564-73.\|[4]Kim, S.J., et al., Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes, 2008. 57(5): p. 1331-9.\|[5]Beconi, M.G., et al. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, 2007. 35(4): p. 525-32. Biochem Pharmacol. 2023 Oct 5:115846.\|Biochim Biophys Acta Mol Basis Dis. 2024 Jul 25:167433.\|Cell Death Dis. 2021 Oct 11;12(10):928.\|Exp Cell Res. 2024 Sep 12;442(2):114254.\|Front Oncol. 24 September 2021.\|iScience. 2023 Feb.\|J Adv Res. 2024 Oct 5:S2090-1232(24)00433-8.\|J Biol Chem. 2018 Dec 7;293(49):18864-18878. \|J Nanobiotechnology. 2024 Oct 16;22(1):631.\|J Sep Sci. 2021 Oct 28.\|Korean J Physiol Pharmacol. 2021 Sep 1;25(5):425-437.\|Life Metab. 2025 Feb 08.\|Neurol Res. 2018 Sep;40(9):736-743.\|Nutr Neurosci. 2018 Apr 26:1-17.\|Nutrition. 2024 Aug 29.\|Orebro University. 2024.\|Oxid Med Cell Longev. 2019 Nov 15;2019:6181754.\|Oxid Med Cell Longev. 2022 May 17;2022:2586305.\|Research Square Preprint. 2024 Apr 25.\|Sci Rep. 2019 Mar 11;9(1):4074.\|Biomed Pharmacother. 2023 Mar 24;162:114555.\|bioRxiv. 2023 Nov 4.
Smiles	O=C(N1CC2=NN=C(C(F)(F)F)N2CC1)C[C@H](N)CC3=CC(F)=C(F)C=C3F
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK-0431
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	Autophagy; Dipeptidyl Peptidase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	407.31
Product Description	Sitagliptin (MK-0431) is a potent and orally active inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts[1].
Manufacturer - Research Area	Metabolic Disease; Cancer
Solubility	DMSO : ≥ 100 mg/mL
Manufacturer - Pathway	Autophagy; Metabolic Enzyme/Protease
Clinical information	Launched
Isoform	DPP-4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.